Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
NCT ID: NCT04253145
Last Updated: 2023-11-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
184 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-12-13
Study Completion Date
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Prospective, open-label, uncontrolled and multicenter phase I-II study in SCLC patients with ECOG PS 0-1 who have failed one prior platinum-containing line but no more than one chemotherapy-containing line. The study will be divided into two parts: a dose-ranging phase I with escalating doses of PM01183 in combination with a fixed dose of atezolizumab, followed by a single-arm phase II part with expansion at the RD determined during the phase I.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
NCT03059667
Small Cell Lung Cancer
Small Cell Lung Cancer Limited Stage
Small Cell Lung Cancer Extensive Stage
COMPLETED
PHASE2
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02367781
Carcinoma, Non-Squamous Non-Small Cell Lung
COMPLETED
PHASE3
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
NCT04832854
Non-Small Cell Lung Cancer (NSCLC)
COMPLETED
PHASE2
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718
Non-Small Cell Lung Cancer
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
NCT05171777
Non-small Cell Lung Cancer
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase I Patients will receive atezolizumab at a fixed dose of 1200 mg intravenously (i.v.) followed by PM01183 at a starting dose of 2.5 mg/m2 i.v. as a 1-hour infusion on Day 1 every three weeks (q3wk). PM01183 doses will be escalated in successive cohorts of patients following a modified Fibonacci scheme and a classical 3+3 design, and according to observed tolerance and safety.
Phase II Patients will receive atezolizumab i.v. as a 60-minute infusion (the second and subsequent infusions may be administered over 30 minutes) followed by PM01183 i.v. as a 1-hour infusion on Day 1 q3wk, at the RD determined during the phase I part.
It is expected that approximately 50% of patients included were previously treated with chemotherapy and the other 50% with immunotherapy and chemotherapy. In case one of the groups reaches 50% of the total number of patients expected to be recruited, no further patient will be included in this group and accrual will be limited to patients with the other group.
It is expected that approximately 50% of the patients included in the phase II part will be platinum-resistant \[i.e., chemotherapy-free interval (CTFI) 30 to \< 90 days from the end of first-line platinum-based chemotherapy\] and 50% will be platinum-sensitive (i.e., CTFI ≥ 90 days), so as to assess efficacy in both settings. However in case that one of the CTFI groups reaches 60% of the total number of patients expected to be recruited, no further patient will be included in this group and accrual will be limited to patients with the other CTFI group.
Phase II Patients will receive atezolizumab i.v. as a 60-minute infusion (the second and subsequent infusions may be administered over 30 minutes) followed by PM01183 i.v. as a 1-hour infusion on Day 1 q3wk, at the RD determined during the phase I part.
It is expected that approximately 50% of patients included were previously treated with chemotherapy and the other 50% with immunotherapy and chemotherapy. In case one of the groups reaches 50% of the total number of patients expected to be recruited, no further patient will be included in this group and accrual will be limited to patients with the other group.
It is expected that approximately 50% of the patients included in the phase II part will be platinum-resistant \[i.e., chemotherapy-free interval (CTFI) 30 to \< 90 days from the end of first-line platinum-based chemotherapy\] and 50% will be platinum-sensitive (i.e., CTFI ≥ 90 days), so as to assess efficacy in both settings. However in case that one of the CTFI groups reaches 60% of the total number of patients expected to be recruited, no further patient will be included in this group and accrual will be limited to patients with the other CTFI group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Carcinoma, Small Cell Lung
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Prospective, open-label, uncontrolled and multicenter phase I-II study
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PM01183 w/ Atezolizumab
Patients will receive atezolizumab at a fixed dose of 1200 mg intravenously (i.v.) as a 60-minute infusion (the second and subsequent infusions may be administered over 30 minutes) followed by PM01183 at a starting dose of 2.5 mg/m2 i.v. as a 1-hour infusion on Day 1 every three weeks (q3wk). Following analysis of cohorts, dose levels can be escalated from 2.5mg to 3.2, to a maximum dose of 3.5 mg of PM01183
Group Type
EXPERIMENTAL
PM 01183
Intervention Type
DRUG
Lyophilisate for solution for infusion
Atezolizumab
Intervention Type
DRUG
Concentrate for solution for infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PM 01183
Lyophilisate for solution for infusion
Intervention Type
DRUG
Atezolizumab
Concentrate for solution for infusion
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Lurbinectidin
Tecentriq
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Voluntarily signed and dated written informed consent prior to any specific study procedure.
* Age \>18 years.
* Histologically or cytologically confirmed diagnosis of extensive or limited SCLC.
* Progression to first-line platinum-based chemotherapy. For phase II part: Progression to first- line platinum-based chemotherapy or first- line platinum- based chemotherapy and immunoterapy (anti PD1/ PDL1). A chemotherapy and/ or immunotherapy- free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) ≥ 30 days.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score ≤1.
* Measurable disease according to RECIST v.1.1. Note: irradiated lesions may qualify as target if progression has been documented.
* At least three weeks since last prior anticancer treatment (including radiotherapy) and recovery to grade ≤ 1 from any adverse event (AE) related to previous anticancer treatment (excluding sensory neuropathy, anemia, asthenia and alopecia, all grade ≤ 2) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v.5).
* Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤7 days before inclusion in the study):
* Platelet count ≥100 x 109/L, hemoglobin ≥9.0 g/dL and absolute neutrophil count (ANC) ≥1.5 x 109/L.
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 x the upper limit of normal (ULN), independently of the presence of liver metastases.
* Alkaline phosphatase (AP) ≤2.5 x ULN.
* Total bilirubin ≤1.5 x ULN or direct bilirubin ≤ULN
* International Normalized Ratio (INR) \<1.5 (except if patient is on oral anticoagulation therapy).
* Calculated creatinine clearance (CrCL) ≥30 mL/minute (using Cockcroft and Gault´s formula).
* Creatine phosphokinase (CPK) ≤2.5 x ULN.
* Albumin ≥3.0 g/dL. Albumin infusion to fulfill the inclusion criterion is forbidden.
* Thyroid stimulating hormone (TSH) within institutional normal limits. If TSH is above the ULN, then a free T4 within institutional normal limits is acceptable.
* Evidence of non-childbearing status for women of childbearing potential (WOCBP). Both women and men must agree to use a highly effective contraceptive measure during the trial, for at least five months after last atezolizumab dose, and for at least six weeks (women) or 4 months (men) after last PM01183 dose. Fertile male patients with WOCBP partners must agree to refrain from fathering a child or donating sperm during the trial and up to five months after treatment discontinuation. Acceptable methods of contraception include abstinence, intrauterine device (IUD), oral contraceptive, subdermal implant and/or double barrier.
* Age \>18 years.
* Histologically or cytologically confirmed diagnosis of extensive or limited SCLC.
* Progression to first-line platinum-based chemotherapy. For phase II part: Progression to first- line platinum-based chemotherapy or first- line platinum- based chemotherapy and immunoterapy (anti PD1/ PDL1). A chemotherapy and/ or immunotherapy- free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) ≥ 30 days.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score ≤1.
* Measurable disease according to RECIST v.1.1. Note: irradiated lesions may qualify as target if progression has been documented.
* At least three weeks since last prior anticancer treatment (including radiotherapy) and recovery to grade ≤ 1 from any adverse event (AE) related to previous anticancer treatment (excluding sensory neuropathy, anemia, asthenia and alopecia, all grade ≤ 2) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v.5).
* Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤7 days before inclusion in the study):
* Platelet count ≥100 x 109/L, hemoglobin ≥9.0 g/dL and absolute neutrophil count (ANC) ≥1.5 x 109/L.
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 x the upper limit of normal (ULN), independently of the presence of liver metastases.
* Alkaline phosphatase (AP) ≤2.5 x ULN.
* Total bilirubin ≤1.5 x ULN or direct bilirubin ≤ULN
* International Normalized Ratio (INR) \<1.5 (except if patient is on oral anticoagulation therapy).
* Calculated creatinine clearance (CrCL) ≥30 mL/minute (using Cockcroft and Gault´s formula).
* Creatine phosphokinase (CPK) ≤2.5 x ULN.
* Albumin ≥3.0 g/dL. Albumin infusion to fulfill the inclusion criterion is forbidden.
* Thyroid stimulating hormone (TSH) within institutional normal limits. If TSH is above the ULN, then a free T4 within institutional normal limits is acceptable.
* Evidence of non-childbearing status for women of childbearing potential (WOCBP). Both women and men must agree to use a highly effective contraceptive measure during the trial, for at least five months after last atezolizumab dose, and for at least six weeks (women) or 4 months (men) after last PM01183 dose. Fertile male patients with WOCBP partners must agree to refrain from fathering a child or donating sperm during the trial and up to five months after treatment discontinuation. Acceptable methods of contraception include abstinence, intrauterine device (IUD), oral contraceptive, subdermal implant and/or double barrier.
Exclusion Criteria
1. Active or untreated central nervous system (CNS) involvement. Treated CNS metastases have to show radiographic stability (defined as no CNS progression for at least three weeks from post-radiotherapy brain scan to brain scan performed prior study entry), and patients should not have neurologic sign/symptoms secondary to the brain metastases or RT. Any steroid treatment must be completed ≥ 14 days before first dose of study treatment.
2. More than one prior chemotherapy-containing line (re-challenge with the same initial regimen is not allowed).
3. Patients with radiation therapy (RT) in more than 35% of the bone marrow.
4. History of previous bone marrow and/or stem cell transplantation.
5. Impending need for RT (e.g., painful bone metastasis and/or risk of spinal cord compression).
6. History of allergy or hypersensitivity to any of the study drugs or their excipients.
7. Prior therapy with PM01183, antibodies against PD-1, PD-L1, PD-L2, CD137, or cytotoxic T lymphocyte associated antigen-4 (CTLA-4). For phase II part: Prior therapy with PM01183, PD-L2, CD137, or cytotoxic T lymphocyte associated antigen-4 (CTLA-4).
8. Live vaccines within 30 days prior to start of study treatment and while on treatment.
9. History of other prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer. Patients with other prior malignancies and no disease recurrence for 3 years are eligible.
10. Concomitant diseases/conditions:
1. History or presence of unstable angina, myocardial infarction, congestive heart failure defined as abnormal left ventricular ejection fraction (LVEF) \< 50% assessed by multiple-gated acquisition scan (MUGA) or equivalent by ultrasound (US), or clinically significant valvular heart disease within 12 months prior first study dose.
2. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment.
3. Ongoing chronic alcohol consumption, or cirrhosis with Child-Pugh score B or C.
4. Active uncontrolled infection. Serious non-healing wound, ulcer or bone fracture.
5. Diagnose of immunodeficiency or receiving systemic steroids therapy (more than a daily dose of 10 mg of prednisone or equivalent per day) or any other form of immunosuppressive therapy within 14 days prior to the first study dose.
6. Active autoimmune disease that required systemic treatment in the past two years (i.e., with disease-modifying agents, corticosteroids and immunosuppressive drugs).
Patients with vitiligo or resolved childhood asthma/atopy are eligible, as well as patients who require intermittent use of bronchodilators or local steroid injections, patients with hypothyroidism stable on hormone replacement, patients with insulin-treated controlled type 1 diabetes or Sjogren's syndrome.
7. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis or evidence of active pneumonitis on screening chest computed tomography (CT) scans. A history of radiation pneumonitis in radiation field (fibrosis) will be allowed if asymptomatic and not requiring steroids.
8. Known history of active tuberculosis (Mycobacterium tuberculosis).
9. Ongoing treatment-requiring, non-neoplastic chronic liver disease of any origin. For hepatitis B, this includes positive tests for both Hepatitis B surface antigen (HBsAg) and quantitative Hepatitis B polymerase chain reaction (PCR). For hepatitis C, this includes positive tests for both Hepatitis C antibody and quantitative Hepatitis C PCR. Patients taking hepatitis-related antiviral therapy within 6 months prior to the first study dose will also be excluded.
10. Known human immunodeficiency virus (HIV) infection.
11. Myopathy or any clinical situation that causes significant and persistent elevation of CPK (\>2.5 x ULN in two different determinations performed one week apart).
12. Limitation of the patient's ability to comply with the treatment or follow-up procedures.
13. Patiens who have previously experienced pericarditis, pericardial effusion and cardiac tamponade) on prior treatment with other immune- stimulatory anticancer agents.
14. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.
11. Active COVID19 infection determined by PCR (positive result of SARS-CoV-2 virus), not mandatory if fully vaccinated.
2. More than one prior chemotherapy-containing line (re-challenge with the same initial regimen is not allowed).
3. Patients with radiation therapy (RT) in more than 35% of the bone marrow.
4. History of previous bone marrow and/or stem cell transplantation.
5. Impending need for RT (e.g., painful bone metastasis and/or risk of spinal cord compression).
6. History of allergy or hypersensitivity to any of the study drugs or their excipients.
7. Prior therapy with PM01183, antibodies against PD-1, PD-L1, PD-L2, CD137, or cytotoxic T lymphocyte associated antigen-4 (CTLA-4). For phase II part: Prior therapy with PM01183, PD-L2, CD137, or cytotoxic T lymphocyte associated antigen-4 (CTLA-4).
8. Live vaccines within 30 days prior to start of study treatment and while on treatment.
9. History of other prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer. Patients with other prior malignancies and no disease recurrence for 3 years are eligible.
10. Concomitant diseases/conditions:
1. History or presence of unstable angina, myocardial infarction, congestive heart failure defined as abnormal left ventricular ejection fraction (LVEF) \< 50% assessed by multiple-gated acquisition scan (MUGA) or equivalent by ultrasound (US), or clinically significant valvular heart disease within 12 months prior first study dose.
2. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment.
3. Ongoing chronic alcohol consumption, or cirrhosis with Child-Pugh score B or C.
4. Active uncontrolled infection. Serious non-healing wound, ulcer or bone fracture.
5. Diagnose of immunodeficiency or receiving systemic steroids therapy (more than a daily dose of 10 mg of prednisone or equivalent per day) or any other form of immunosuppressive therapy within 14 days prior to the first study dose.
6. Active autoimmune disease that required systemic treatment in the past two years (i.e., with disease-modifying agents, corticosteroids and immunosuppressive drugs).
Patients with vitiligo or resolved childhood asthma/atopy are eligible, as well as patients who require intermittent use of bronchodilators or local steroid injections, patients with hypothyroidism stable on hormone replacement, patients with insulin-treated controlled type 1 diabetes or Sjogren's syndrome.
7. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis or evidence of active pneumonitis on screening chest computed tomography (CT) scans. A history of radiation pneumonitis in radiation field (fibrosis) will be allowed if asymptomatic and not requiring steroids.
8. Known history of active tuberculosis (Mycobacterium tuberculosis).
9. Ongoing treatment-requiring, non-neoplastic chronic liver disease of any origin. For hepatitis B, this includes positive tests for both Hepatitis B surface antigen (HBsAg) and quantitative Hepatitis B polymerase chain reaction (PCR). For hepatitis C, this includes positive tests for both Hepatitis C antibody and quantitative Hepatitis C PCR. Patients taking hepatitis-related antiviral therapy within 6 months prior to the first study dose will also be excluded.
10. Known human immunodeficiency virus (HIV) infection.
11. Myopathy or any clinical situation that causes significant and persistent elevation of CPK (\>2.5 x ULN in two different determinations performed one week apart).
12. Limitation of the patient's ability to comply with the treatment or follow-up procedures.
13. Patiens who have previously experienced pericarditis, pericardial effusion and cardiac tamponade) on prior treatment with other immune- stimulatory anticancer agents.
14. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.
11. Active COVID19 infection determined by PCR (positive result of SARS-CoV-2 virus), not mandatory if fully vaccinated.
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundacion Oncosur
NETWORK
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Santiago Ponce, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital 12 de Octubre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Virgen de la Victoria
Málaga, Andalusia, Spain
Site Status
RECRUITING
Hospital Virgen del Rocio
Seville, Andalusia, Spain
Site Status
RECRUITING
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Site Status
RECRUITING
Hospital Vall d'Hebron
Barcelona, Catalonia, Spain
Site Status
RECRUITING
Hospital Universitario Da Coruña
A Coruña, , Spain
Site Status
RECRUITING
Hospital Clínic de Barcelona
Barcelona, , Spain
Site Status
RECRUITING
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Site Status
RECRUITING
Hospital 12 de Octubre
Madrid, , Spain
Site Status
RECRUITING
Hospital Universitario La Paz
Madrid, , Spain
Site Status
RECRUITING
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Site Status
RECRUITING
Hospital Clínico Universitario Virgen de la Arrizaca
Murcia, , Spain
Site Status
RECRUITING
Hospital Universitario Virgen Macarena
Seville, , Spain
Site Status
RECRUITING
Hospital Clínico Universitario Lozano Blesa
Zaragoza, , Spain
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Spain
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2SMALL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer
NCT02848651
COMPLETED
PHASE2
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT07153445
RECRUITING
PHASE2
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
NCT03191786
COMPLETED
PHASE3
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT04513925
COMPLETED
PHASE3
Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC
NCT04920981
COMPLETED
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
NCT02367794
COMPLETED
PHASE3
Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer
NCT02994576
COMPLETED
PHASE2
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797
COMPLETED
PHASE2/PHASE3
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
NCT02813785
COMPLETED
PHASE3
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT02546986
COMPLETED
PHASE2
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
NCT02409342
COMPLETED
PHASE3
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
NCT04924101
COMPLETED
PHASE2
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
NCT03456063
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
NCT02657434
COMPLETED
PHASE3
A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04028050
COMPLETED
PHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
NCT04611776
WITHDRAWN
PHASE2
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
NCT04938817
RECRUITING
PHASE1/PHASE2
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
NCT04221529
COMPLETED
PHASE2
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02366143
COMPLETED
PHASE3
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04256421
COMPLETED
PHASE3
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
NCT04471428
COMPLETED
PHASE3
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT03285763
COMPLETED
PHASE4